Comparison
AOD-9604 vs. Mod GRF (1-29)
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
221231-10-3
863288-34-0
Molecular weight
1815.09 g/mol
3367.9 g/mol
Half-life
0.4 h
0.5 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Mechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
Mod GRF (1-29)
Synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29). Four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) are intended to slow degradation by dipeptidyl peptidase-IV and increase enzymatic stability relative to native GHRH. Like the native hormone and sermorelin, it binds the GHRH receptor on somatotroph cells of the anterior pituitary; mechanistically this is expected to stimulate endogenous growth-hormone release. Unlike the DAC-conjugated CJC-1295 variant, it lacks albumin binding, so its duration of action remains short.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
3
4
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
0
Legal status
Full entries
Frequently asked questions
- What is the difference between AOD-9604 and Mod GRF (1-29)?
- AOD-9604 is classified as "Growth", while Mod GRF (1-29) is classified as "Growth". AOD-9604: Synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone (hGH 176-191). Originally developed by Metabolic Pharmaceuticals as an oral obesity therapy; all phase-2 trials missed the primary endpoint. No marketing approval. The Australian TGA Schedule 4 classification is often misunderstood. Mod GRF (1-29): Tetrasubstituted synthetic analogue of GHRH(1-29), traded on the grey market as "CJC-1295 without DAC". Closely related to sermorelin (GHRH 1-29); a short-acting growth-hormone-releasing-hormone analogue often combined with a GHRP/ghrelin mimetic. Not approved as a medicinal product. Direct human trials of this exact analogue are essentially absent; the factual basis relies on related GHRH(1-29) analogues. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, AOD-9604 or Mod GRF (1-29)?
- The highest available evidence level is "Human RCT" for AOD-9604 and "Human trial" for Mod GRF (1-29). A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of AOD-9604 and Mod GRF (1-29) in Germany and the United States?
- Germany: AOD-9604 — Unapproved, Mod GRF (1-29) — Unapproved. United States: AOD-9604 — Unapproved, Mod GRF (1-29) — Research only. These are factual summaries with source and review date on the individual pages.